Delivering Innovative Renal
and Vascular Therapies


Developing novel, first-in-class pharmaceuticals to address the
medical needs of patients with renal and vascular diseases


Learn More


Addressing Vascular Access
Failure in Hemodialysis


Improving vascular access outcomes would provide a
lasting benefit to hemodialysis patients


Learn More


Learn More
About PRT-201


An investigational drug for the reduction of vascular
access failure for patients receiving hemodialysis


WATCH NOW

WHO WE ARE

We are a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with renal and vascular diseases. Proteon Therapeutics’ first drug candidate, PRT-201, is a locally-acting recombinant human elastase that fragments elastin fibers in blood vessel walls. PRT-201 has received fast track and orphan drug designations from the FDA and orphan medicinal product designation from the European Commission for hemodialysis vascular access indications. Proteon is investigating whether elastase could be used as a treatment to dilate arteries and veins and to reduce neointimal hyperplasia in settings where such effects would result in a medical benefit.

 

LEARN MORE

NEWS

All News      Subscribe to Proteon News